Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abequolixron - Inspirna

Next Previous
Drug Profile

Abequolixron - Inspirna

Alternative Names: Abequolixron zinc; RGX-104; RGX-104 Zinc; SB-742881

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer AstraZeneca; Inspirna; UNC Lineberger Comprehensive Cancer Center
  • Class Acetic acids; Amines; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Immunotherapies; Small molecules
  • Mechanism of Action Dendritic cell stimulants; Liver X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Glioblastoma; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 27 Feb 2025 UNC Lineberger Comprehensive Cancer Center terminates a phase-I clinical trials in Non-small cell lung cancer (Combination therapy) in USA (PO) as sponsor is closing the trial (NCT05911308)
  • 22 Jan 2025 Inspirna completes a phase-I/II clinical trials in Solid tumours and Lymphoma (Late-stage disease, Combination therapy, Metastatic disease, unresectable/Inoperable) in USA (PO) (NCT02922764)
  • 01 Apr 2024 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy) in USA (PO) (NCT05911308)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top